Skip to content

Hypertension

Three international guidelines are covered. AHA/ACC 2025 and ESC 2024 are the newest. ISH 2020 is older but is written for low- and middle-income settings, which makes it useful in Bangladesh, where no current national hypertension guideline is published online.

AHA/ACC 2025

International Current

2025 AHA/ACC/Multisociety Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults

Official source

ESC 2024

International Current

2024 ESC Guidelines for the management of elevated blood pressure and hypertension

Official source

ISH 2020

International Current

2020 International Society of Hypertension Global Hypertension Practice Guidelines

Official source

Where they agree

  • First-line drugs: ACE inhibitor or ARB, long-acting dihydropyridine CCB, and thiazide or thiazide-like diuretic. Beta-blockers are added only for a compelling indication such as angina, post-MI, HFrEF or rate control.
  • Start with two drugs for most people with BP ≥140/90, ideally in a single pill.
  • Never combine an ACE inhibitor with an ARB.
  • Confirm the diagnosis with out-of-office BP (home or ambulatory) when possible.
  • Resistant hypertension: after ACEi/ARB + CCB + thiazide-like diuretic, the fourth drug is spironolactone.
  • Lifestyle for everyone: cut salt, follow a DASH/Mediterranean-style diet, lose weight, exercise and limit alcohol.

Where they differ

AHA/ACC 2025 ESC 2024 ISH 2020
Categories (office) Normal <120/<80 · Elevated 120–129/<80 · Stage 1 130–139 or 80–89 · Stage 2 ≥140 or ≥90 Non-elevated <120/70 · Elevated 120–139/70–89 · Hypertension ≥140/90 Normal <130/85 · High-normal 130–139/85–89 · Grade 1 140–159/90–99 · Grade 2 ≥160/100
Hypertension starts at ≥130/80 ≥140/90 ≥140/90
Home BP threshold for hypertension ≥130/80 (stage 1), ≥135/85 (stage 2) ≥135/85 ≥135/85
Risk calculator PREVENT (10-year CVD risk) SCORE2 / SCORE2-OP Simplified risk table
"High risk" cut-off PREVENT ≥7.5% SCORE2 ≥10% (or 5–<10% + risk modifiers) CVD, CKD, diabetes, HMOD
Drugs at 130–139/80–89 Start now if CVD, diabetes, CKD or PREVENT ≥7.5%. Otherwise after 3–6 months of lifestyle if still ≥130/80 Only if high risk, after 3 months of lifestyle Lifestyle; drugs only for a compelling indication
Target <130/80, encourage SBP <120 SBP 120–129, DBP 70–79 if tolerated (ALARA if not) Essential: ≥20/10 fall, ideally <140/90. Optimal: <130/80 if <65 y; <140/90 if ≥65 y
Initial monotherapy is fine for Stage 1 Elevated BP, age ≥85, frailty, symptomatic orthostatic hypotension Low-risk grade 1, very old (≥80), frail
Acute ICH SBP 150–220: lower to 130–<140 and keep ≥7 days Lower to SBP 140–160 within 6 h Not covered in detail
Renal denervation 2b (selected resistant HTN) IIb (medium/high-volume centre); III as first-line Not covered

Clinical pearls

  • AHA keeps the 2017 categories (stage 1 starts at 130/80). ESC and ISH still define hypertension at ≥140/90.
  • AHA 2025 swaps the Pooled Cohort Equations for PREVENT, with a 7.5% 10-year CVD risk threshold.
  • ESC 2024 brought in the "elevated BP" category (120–139/70–89) and a target range of 120–129 systolic.
  • In acute ICH, AHA aims lower (130–<140) and ESC aims higher (140–160).
  • In pregnancy, all three avoid ACE inhibitors and ARBs. Labetalol and extended-release nifedipine are the preferred drugs (ESC also lists methyldopa).